Oligonucleotide chip for detection of Lamivudine-resistant hepatitis B virus.
Hepatitis B virus (HBV) is one of the major causes of liver disease worldwide. It is important to conduct antiviral therapy against chronic hepatitis B to minimize the amount of liver damage. Lamivudine has been known to be an effective antiviral agent for the treatment of HBV infection. However, the emergence of viral mutants resistant to lamivudine is the main concern during the treatment of HBV-infected patients. Therefore, the detection of lamivudine-resistant mutants is of clinical importance. We have developed an oligonucleotide chip for the detection of lamivudine-resistant HBV which is rapid and accurate. The oligonucleotide chip consists of quality control probes, negative control probes, and specific oligonucleotide probes for the detection of lamivudine-resistant HBV. The specific probes consist of five probes for the detection of wild-type rtL180, rtM204, and rtV207 sequences and seven probes for the detection of HBV mutations. We tested 123 serum samples from patients with chronic HBV infection who had received lamivudine therapy. Eighty samples contained mutants with YMDD mutations. Among these, 17 contained rtM204V (YVDD), 24 contained rtM204I3 (YIDD3), 3 contained rtM204I2 (YIDD2), and 36 contained mixed types. We compared the results obtained with our oligonucleotide chip with those obtained by PCR-restriction fragment length polymorphism (RFLP) analysis and sequencing. The rate of concordance between the assay with the oligonucleotide chip and PCR-RFLP analysis for detection of the YMDD motif was 96.7%. The rate of concordance between the results obtained with the oligonucleotide chip for the detection of rtL180 and rtV207 and the results obtained by sequencing was 100%. Thus, the oligonucleotide chip is a reliable and useful tool for the detection of antiviral-resistant HBV.
Jang
Hyunjung
H
Department of Microbiology, College of Medicine, Pusan National University, #10 1-Ga Ami-Dong Seo-Gu, Busan 602-739, Korea.
Cho
Mong
M
Heo
Jeong
J
Kim
Hyunghoi
H
Jun
Hongki
H
Shin
Woowon
W
Cho
Byungman
B
Park
Heekyung
H
Kim
Cheolmin
C
D017931:DNA Primers; D004279:DNA, Viral / Q000097:blood / Q000302:isolation & purification; D024882:Drug Resistance, Viral; D006509:Hepatitis B / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology*; D016297:Mutagenesis, Site-Directed; D020411:Oligonucleotide Array Sequence Analysis; D015345:Oligonucleotide Probes; D012680:Sensitivity and Specificity
D017931:DNA Primers; D004279:DNA, Viral; D015345:Oligonucleotide Probes; D019259:Lamivudine